People in Australia with Alzheimer’s disease who have finished five years of treatment with Anavex 2-73 (blarcamesine) in Phase 2 clinical trials may continue to use Anavex Life Sciences‘ investigational oral therapy at their doctor’s request. Under a special access scheme, the Therapeutic Goods Administration (TGA) — a…
A type of mouth bacteria involved in gum disease is able to infect human brain cells, new research shows. The infection results in cellular changes that are similar to what is seen in Alzheimer’s, supporting a link between the bacteria and the neurodegenerative disease. The findings were presented at…
Cassava Sciences‘s investigational therapy PTI-125 failed to significantly lower the levels of Alzheimer’s-relevant biomarkers present in fluid surrounding the brain and spinal cord of patients, according to results from a Phase 2b clinical trial. The company announced it will study these topline data in deciding next…
Taking daily low-dose aspirin does not seem to reduce the risk of dementia, cognitive decline, or Alzheimer’s disease, new clinical trial data show. The results were published in Neurology in a study, titled “Randomized placebo-controlled trial of the effects of aspirin on dementia and cognitive decline.”…
Axsome Therapeutics is planning to complete its ADVANCE-1 clinical trial, evaluating AXS-05 as a treatment for agitation in Alzheimer’s disease, a few months earlier to ensure the safety of study participants during the COVID-19 pandemic. Top-line results from this Phase 2/3 trial, which opened in 2017, are now expected…
Biogen is acquiring from Pfizer investigational therapy PF-05251749, a small molecule being developed to treat sundowning in Alzheimer’s disease and irregular sleep wake rhythm disorder (ISWRD) in Parkinson’s disease. The company plans to begin a Phase 1b clinical trial by the end of this year,…
Longer sequence repeats in or near two genes may be linked to a higher risk of late-onset Alzheimer’s disease, a study reports. The study “Alzheimer Disease Pathology-Associated Polymorphism in a Complex Variable Number of Tandem Repeat Region Within the MUC6 Gene, Near the AP2A2 Gene” was…
A newly opened Phase 2 clinical trial will test the sensitivity of new imaging tool for plaque buildup in the brains of people with mild cognitive impairment and dementia due to Alzheimer’s disease, Aprinoia Therapeutics announced. The trial is set to enroll 130 adults, 50 to 85 years old, a…
A diet that is high in salt can cause dementia in mice by promoting a buildup of plaques of the protein tau, which is also associated with Alzheimer’s disease, a new study shows. The study, titled “Dietary salt promotes cognitive impairment through tau phosphorylation,” was published in …
NeuroEM Therapeutics‘s MemorEMTM — a head-worn device that uses electromagnetic waves — has shown promising results in a preliminary clinical trial of people with mild-to-moderate Alzheimer’s disease. Seven of eight participants demonstrated improved memory after two months of treatment. The results, “A Clinical Trial of Transcranial Electromagnetic Treatment…
Get regular updates to your inbox.